According to Science Advances, BASF owns just less than 50% of the patents in the marine genetics; about 84% patents are owned by companies and 12% are assigned to Public and private universities. By 2025 global market is estimated to adapt the commercial use of marine genetics in pharma, biofuel and chemical industries.
Bayer has completed the acquisition of US-based biotech company Monsanto to become the world’s biggest agrochemical and seed company. The deal value is of USD 63 Billion. This integration of Monsanto to Bayer would occur in roughly around two months after divestment of certain assets to BASF gets completed, till that Monsanto will operate independently.
Recently on 5th June FDA approved Fulphila, a biosimilar drug to Neulasta for reducing the risk of infections during treatment of cancer. FDA has granted approval of this drug to Mylan GmbH. This biosimilar drug helps to reduce the chances of infections in patients with non-myeloid cancer receiving myelosuppressive chemotherapy. This chemotherapy tends to produce a clinically significant incidence of febrile neutropenia. Fulphila used to suppress these symptoms of febrile neutropenia produced during myelosuppressive chemotherapy
Engineer’s at MIT have developed a compression bandage woven from pressure-sensing photonic fibers for applying optimal pressure onto the affected area in compression therapy. The fibers serve as a continuous pressure sensor which helps the caregivers or patients to determine the degree of loosening or tightening of the bandage needed based on the change in color of the fibers.
Gelx (Manufactured by Big Pharma), recently received European Regulatory Approval based on the clinical data with 99.3% of patients experienced the prevention or remission during cancer treatment. Now, it is the first medical product which can be used in the treatment and prevention of oral mucositis in both adults as well as children’s allowing them to continue with a nutritional program under cancer treatment
Aimovig also known as erenumab is the first FDA approved a new class of drug which is used for preventive treatment of a migraine. The drug has passed three clinical trial phases and the efficacy of the drug is calculated during trials. Grant of the drug is approved by FDA to Amgen. Moreover, the most common side effect observed during clinical trials are injection site reaction and constipation.
China based company Lepu Medical Technology infiltrate into Indian medical device market as a subsidiary named as Lepucare (India) Vascular Solutions Pvt. Ltd. Company has products for diagnosing vascular condition in cardiac, neuro and peripheral region of the body.
AstraZeneca filed its second law suit against Nativa as it is marketing a copy version of AstraZeneca’s Iressa (lung cancer drug), whose patent is still in force. This legal battle is started since mid of last year.
Artificial cells can be controlled by its function and hence it can be considered as one of the supreme models for biological research and its application as a substitute for natural cells or tissue or organ. Researchers of Imperial College London and Loughborough University have used Lasers to arrange the cells and have got success to form a basic tissue structure which is a prompting step towards the development of a new generation biomaterial.
Protein analysis is a prime concept for the pharmaceutical development as well as to examine the diseased and healthy state. Scientists of ‘University at Buffalo’ have developed a new protein analysis tool, IonStar, and they claimed, it gives the quick and increased accuracy of proteomics data even with the low amount of protein sample.